Cocrystal Pharma Inc
For the period ended Sep 30, 2024. Filed Nov 13, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 13, 2024
COCP$1.11+6.3%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations
(in thousands, except per share data)
| Three months ended September 30, | Nine months ended September 30, | |||
|---|---|---|---|---|
| 2024 | 2023 | 2024 | 2023 | |
| Operating expenses: | ||||
| Research and development | 3,242 | 4,194 | 10,500 | 10,902 |
| General and administrative | 1,800 | 1,849 | 4,148 | 4,591 |
| Legal settlement | - | (1,600) | - | (1,600) |
| Total operating expenses | 5,042 | 4,443 | 14,648 | 13,893 |
| Loss from operations | (5,042) | (4,443) | (14,648) | (13,893) |
| Other income (expense): | ||||
| Interest income (expense), net | 111 | 320 | 482 | 460 |
| Foreign exchange loss | (8) | (42) | (72) | (87) |
| Total other expense, net | 103 | 278 | 410 | 373 |
| Net loss | $(4,939) | $(4,165) | (14,238) | (13,520) |
| Net loss per common share, basic and diluted | $(0.49) | $(0.41) | (1.40) | (1.43) |
| Weighted average number of common shares, basic and diluted | 10,174 | 10,153 | 10,174 | 9,461 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.